Comparison of Fluticasone Furoate and Fexofenadine hydrochloride as initial treatment for Japanese cedar pollinosis: single-center,randomized,parallel-group study

Comparison of Fluticasone Furoate and Fexofenadine hydrochloride as initial treatment for Japanese cedar pollinosis: single-center,randomized,parallel-group study - Comparison of Fluticasone Furoate and Fexofenadine hydrochloride as initial treatment for Japanese cedar pollinosis: single-center,randomized,parallel-group study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004930

Enrollment

Registered

2011-01-22

Start date

2011-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanese cedar pollinosis

Interventions

Fluticasone furoate puff per nostril once a day 110&amp

micro

g is administered as initial treatment for Japanese cedar pollinosis. 60mg of Fexofenadine orally twice a day can be used as a backup drug. 60mg of Fexofenadine orally twice a day is administered

g can be used as a backup drug.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed with Japanese cedar pollinosis and who desire initial therapy and meet following requirements 1)A history of Japanese cedar pollinosis for at least one season before study entry 2)patient can write down the pollinosis-dairy of this study appropriately from the doctor's viewpoint 3)patient can keep the rule of this study and doctor's direction from the doctor's viewpoint 4)obtain informed consent before registration to this study 5)Patient aged 15 years and above when doctors obtain informed consent

Exclusion criteria

Exclusion criteria: 1)patient experienced adverse effect by components of study drug 2)patients who is pregnant or suspected of pregnancy , wish to get pregnant , nursing mom 3)inappropriate patient for this study from the doctor's viewpoint

Design outcomes

Primary

Measure	Time frame
Total nasal symptom score	—

Secondary

Measure	Time frame
Total ocular symptom score, Japan Rhinoconjunctivitis QOL Questionaire	—

Countries

Japan

Contacts

Public ContactMikiya Asako

Kansai Medical University Hirakata Hospital Otolaryngology Head and neck surgery

072-804-0101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026